Abstract 2123
Background
Molecular characterization of low grade gliomas (LGG) has improved in recent years and is essential for diagnosis and treatment of these diseases. Moreover, clinical factors, such as age and the extent of surgery retain a prognostic role in LGG that were assessed for IDH1/2, 1p/19q codeletion, and MGMT methylation status.
Methods
we retrospectively evaluated all adult LGG patients (pts) from our data warehouse who received surgery and had sufficient tissue to assess biomarkers characterization. IDH1/2 assessment was performed on formalin-fixed paraffin-embedded samples by PCR, MGMT by methylation specific PCR, 1p/19 codeletion by FISH.
Results
198 consecutive LGG were included. The median age was 38 (range:18–72). Median follow up was 74.0 months, 109 pts (55.1%) were
Conclusions
Molecular characteristic of LGG define the prognosis of these tumors. Moreover, clinical risk assessment retains a role even in the era of molecular characterization.
Clinical trial identification
Legal entity responsible for the study
Azienda USL / IRCCS Institute of Neurological Sciences of Bologna
Funding
Azienda USL / IRCCS Institute of Neurological Sciences of Bologna
Disclosure
All authors have declared no conflicts of interest.